Cellectar Biosciences Inc (NASDAQ:CLRB)is a pharmaceutical stock thats popping up on everyones radar. This week has been an criticalweek for CLRB, as it blasted higher out of a key low consolidation on a strong jump in volume. The catalyst appears to be the CLRBs announcement this week that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that show significantly improved pharmacologic activity versus the payload molecule alone.

According to the release, utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the companys PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells.

Cellectar Biosciences Inc (NASDAQ:CLRB) bills itself as a company developing agents to detect, treat and monitor a broad spectrum of cancers.

Utilizing a novel phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, CLRBs compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent.

A Phase II trial evaluating I-124-CLR1404 in glioblastoma is expected to be completed in 2014. Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors is anticipated in the first quarter of 2014. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

CLRB was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Find outwhen $CLRB reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, CLRB just popped off a key technical low on the companys announcement that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that apparently show significant improved pharmacologic activity versus the payload molecule alone. That could be huge news for the company.

The rapid advancement and positive data from these research programs, coupled with our ongoing collaborations, further validate the unique capabilities and broad utility of our PDC platform, said Jim Caruso, president and CEO of Cellectar Biosciences. We continue to drive our key internal programs in a strategic and cost-efficient manner including the advancement of candidate molecules from these new compound series. The company anticipates sharing additional technical details of this work either in peer reviewed journal articles or at a future oncology conference.

Recent action has seen 15% piled on for shareholders of the company during the trailing week, a bounce that has taken root amid largely bearish action over the larger time frame. Market participants may want to pay attention to this stock. CLRB is a stock whose past is littered with sudden rips. Whats more, the listing has seen interest climb, with an increase in recent trading volume of just shy of 150% over what the stock has registered over the longer term.

Earning a current market cap value of $24.92M, CLRBhas a significant war chest ($8.4M) of cash on the books, which is balanced by virtually no total current liabilities. The company is pre-revenue at this point. This is an exciting story, and we look forward to a follow-up chapter as events transpire.For continuing coverage on shares of $CLRB stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next breakoutpick!

Disclosure: We hold no position in $CLRB, either long or short, and we have not been compensated for this article.

See the original post:
Cellectar Biosciences Inc (NASDAQ:CLRB) Pops Higher on Strong Research Data - The Oracle Dispatch

.......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........

Dr. Nichol: If your cockapoo has somewhat bowed rear legs, one or both of her knee caps (patellas) may slip out of its groove at the lower end of her thigh bone. Some patellas dislocate (luxate) just occasionally. A dog may skip for a few steps and then use the leg normally again after the patella slips back into the groove.

The knees of a dog with luxating patellas are vulnerable to injury. Your girls missed jump may have strained the supportive tendons that guide her patella. Rest and anti-inflammatory medication can help in the short term but the anatomy would still be structurally unsound. The only permanent solution will be surgical remodeling of the attachment of her patella and the groove in her lower femur.

Called a tibial crest rotation this surgery is a long-established procedure that many veterinarians are skilled at performing. But even with the geometric forces corrected, some chronic damage to a dogs tendons and cartilage will remain. Thats what makes stem cell therapy valuable.

While your girl is under anesthesia for knee surgery her doctor can make a small abdominal incision and remove a bit of fat. Your dogs very own stem cells (no risk of rejection) will be processed and shipped back overnight for injection into her knee. Over the following weeks the stem cells will stimulate regeneration of chronically inflamed tissues, resulting in a stronger and more comfortable joint.

Finally, stem cell therapy, also known as regenerative medicine, is not new. Veterinary orthopedists have used stem cells for 15 years to speed healing and reach better long-term outcomes.

Each week I make a short video or podcast to help bring out the best in pets. Sign up at no charge on my website, drjeffnichol.com. Every Tuesday it will arrive in your email. Ill also send you my free Pet Emergency and CPR guide.

Dr. Jeff Nichol treats behavior disorders at the Veterinary Emergency & Specialty Centers in Albuquerque and Santa Fe (505-792-5131). Questions on pet behavioral or physical concerns? For answers, Like my Facebook page at facebook.com/drjeffnichol or by mail to 4000 Montgomery NE, Albuquerque, NM 87109.

Excerpt from:
Stem cells could benefit cockapoo's knee issue - Albuquerque Journal

Julie Gould was heartbroken to learn that there was no cure for diffuse scleroderma, the chronic disease that she was diagnosed with in 2016.

Julie Gould was heartbroken to learn that there was no cure for diffuse scleroderma, the chronic disease that she was diagnosed with in 2016.The life-threatening auto-immune disease affects connective tissue in the body by producing too much collagen and hardening cartilage, tendons and skin.

I was depressed when I received the initial diagnosis, she said. It's difficult to hear that you may be dead in five years time. According to the Scleroderma Foundation, A person newly diagnosed with scleroderma may feel alone and uncertain about where to turn for help. He or she may experience a number of other feelings and emotional reactions from time to time, including initial shock or disbelief, fear, anger, denial, self-blame, guilt, grief, sadness or depression. Family members may have similar feelings.

When Julie first consulted a doctor in 2015, she was concerned that she might have picked up an infectious disease, such as a mosquito-born illness, or as she described it, the worst flu ever, during a vacation to Mexico. But she was told that diabetic neuropathy was causing the pins and needles tingling in her hands and feet.

My hands and feet continued to swell and I thought I had heart failure, said Julie. I went to a cardiologist to see if that was the problem. Those tests and lab work came back normal too.When the pain and swelling became excruciating, she consulted with a rheumatologist. When diabetic neuropathy was ruled out, she was told it could be rheumatoid arthritis. Although the lab tests were within normal limits, her doctor thought the labs werent correlating yet because it was so early in diagnosis. She was given medication and told to come back in six weeks, but saw no alleviation of the pain.

When her rheumatologist told her she might have scleroderma and ordered lab work, those tests too were normal.My physical therapist thought I should go to the Mayo Clinic, said Julie. I got online and requested an appointment. Three months later at the clinic in Rochester, Minnesota, she was diagnosed with diffuse scleroderma but it was a rare type that doesnt test positive in the usual lab test. Her total diagnosis wait had been a year and eight months, and she was more than ready to begin treatment. She was given multiple medications for pain and symptom control.After diagnosis, I got online and started searching for information about scleroderma, said Julie. It was dismal. I had to step away from the computer.Current treatments for the disease are varied, but basically treat the organs being affected. When lung tissue is hardened, patients are tube-fed and given oxygen. Sometimes lung transplants are required. Some patients need gastrointestinal surgery and some have operations to decrease ulcers on their fingers, while some must have their fingers and toes amputated.

Medication for high blood pressure and chemotherapy to suppress the disease are common with the disease and stiff joints and skin can result in patients not being able to stand upright and wheelchair-bound. Physical and occupational therapy is required to save body functions.Julies mother and sister, who is a nurse, also began scouring the internet for treatments. When they read about stem cell transplant they both felt this was the answer to Julies prayers.

Overcome with depression and pain, Julie began taking an antidepressant. With the help of the drug and limitless help and support from her family, the research on transplant gave her much needed hope. When I found out about the transplant, I was scared, said Julie. I feared for my life being taken by this disease.

This disease literally affects every organ system in the body. Transplant offered a chance to stop the disease in its tracks and stop further progression and damage to my body. I had been recently diagnosed, so the doctor said I could wait until I was worse, then have the transplant at a later date. I did not wait. I already had heart, lung, GI, and musculoskeletal systems involved. This approach was proactive, not reactive. It offered me hope.To qualify for stem cell treatment a patient must be sick enough toneed it, but not so sick that they would not benefit from the procedure.

We were able to find many groups to help us learn about scleroderma, she said. Inspire and Facebook were invaluable. There were specific groups for people who had scleroderma. Groups for people who needed a stem cell transplant. Groups for people with scleroderma, who wanted, or who already had a transplant.I started to read all the testimonials. I looked at the NIH website. This was productive research. I was finding out information on how to save my life not on how I was going to die.

After Julie applied for evaluation by Dr. Richard Burt at Northwestern in Chicago, she had scores of tests, including a CT scan of her lungs, MRI of her chest, EKG, sonogram of her heart, heart cath, colonoscopy, EGD, lab work, stress tests, psychological exam, dental exam, and 24-hour urine collection.

After all the anxious waiting during almost two years of doctor visits and tests, Julie was informed that she had passed the evaluation and had been approved for stem cell transplant.I came home to mentally prepare myself, said Julie. I returned to Chicago for the mobilization phase. I received a dose of chemo overnight in the hospital to suppress my immune disease. A week later I then started to give myself injections to produce white blood cells using neupogen. This medication forces the bone marrow to put out extra white blood cells, from which stem cells originate.

After six days of injections, Julie returned to the hospital to have the stem cells removed from her blood for use at a later date. She had to stay in Chicago during this part of treatment in case she had complications from the procedure. The process was similar to dialysis, said Julie. I was at the hospital all day, 12 hours. My own stem cells had been harvested to heal me. After two weeks of rest at home in Leavenworth, Julie returned to Chicago for the transplant. And after five days of more chemo, her stem cells were returned to her body. Now we only had to wait for the transplant to work, said Julie. I stayed in the hospital until the cells engrafted and my immune system started working again. Eight days.I had been in the hospital for 16 days. The transplant is a reboot to your diseased immune system like a reboot to your computer.Julie returned to Leavenworth to rest and recover. My entire family have been tremendously supportive, she said. They offered and provided all of the help that I needed to achieve this treatment.

She is also grateful to the community of Leavenworth for reaching out to help her. They donated money for my out-of-pocket expenses, said Julie. They provided food upon my return from Chicago. I didn't have to cook, nor did my husband for six weeks. Family cleaned my home and watched my children. I was grateful.

Social media also provided support during Julies treatment. She discovered a network of people on Facebook who had already had a transplant, or were waiting to have one. Stem cells are used to treat many auto-immune disorders like multiple sclerosis, lupus, Crohns disease, and many others, said Julie. I could pose any question to this forum and receive an answer. I started my own Facebook page to document my medical treatment so that I too could share my information. It has been wonderful to help others who are experiencing what I have been through.

Julie has just returned from her one-year checkup in Chicago and learned that the progression of the disease has stopped. Stem cell transplant has saved my life, said Julie. I am living, not merely existing.Not only has the disease been stopped in its tracks, Julie has seen physical improvements such as full motion in her shoulder, which was frozen from hardened tissue for much of the last few years. Her contracted hands are also more mobile and she has gained 40 degrees movement in some of her fingers.

I have Raynaud's syndrome, said Julie. It has improved. It was a constant struggle to keep my hands and feet warm. The pain in my hands is mostly gone. The all-over joint pain is gone. The fatigue and malaise are gone. I feel good. I feel happy.As she has regained her back strength and dexterity she is now able to enjoy the routine of normal days, like rising from a chair without pain, sleeping and eating well and even doing simple tasks such as opening a jar, which was difficult after her diagnosis.Everyday tasks were difficult, said Julie. Deodorant, flossing, brushing teeth or hair, dressing. All of the daily activities have gotten easier everyday. The pain is mostly gone.My body feels healthy.

Julie has gained much more than flexibility and relief from constant pain during her long medical challenge, and she emphasizes, I learned to not sweat the small stuff. I learned to live every day. I learned to love every day.

Read more:
IN-DEPTH: Fighting for your life - Leavenworth Times

KTNV Las Vegas

Health Advice | 8/16/17 KTNV Las Vegas Many kids are diagnosed with ADHD--some incorrectly. What may appear to be the behavior of a child with ADHD might actually be symptoms of epilepsy. AdvancedNeuro.net. This segment is sponsored by Advanced Neurodiagnostics & Sleep Center. and more »

See the rest here:
Health Advice | 8/16/17 - KTNV Las Vegas

LEAWOOD, Kan., Aug. 3, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its second quarter 2017 financial results. For the quarter ended June 30, 2017, Aratana reported total net revenues of $5.2 million and a net loss of $10.4 million or $0.26 diluted loss per share.

"We are pleased with the continued customer adoption of Galliprant and Nocita," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "In addition, we continue to advance our next wave of therapeutic candidates as evidenced by several recent regulatory submissions and a positive pivotal efficacy study in cats."

Recent Updates

Financial Results

The second quarter net loss was $10.4 million or $0.26 diluted loss per share compared to net income of $21.2 million or $0.61 diluted net income per share for the corresponding quarter ended June 30, 2016. Aratana recorded $5.2 million in net revenues for the quarter ended June 30, 2017, which primarily includes approximately $3.7 million related to GALLIPRANT product sales as finished goods under its supply arrangement with Elanco, $804 thousand in GALLIPRANT licensing and collaboration revenue, and $637 thousand in NOCITA net product sales. The second quarter of 2016 included $38.1 million in net revenues of which, $38.0 million was the result of the GALLIPRANT Collaboration Agreement.

The cost of product sales totaled $3.7 million in the second quarter of 2017 in comparison to $1.7 million for the corresponding period in 2016. The increase in the second quarter of 2017 was primarily due to GALLIPRANT supply sold to Elanco for commercial distribution, as well as cost of product sales of NOCITA. In July, pursuant to our Collaboration Agreement, Elanco provided notice of its intent to assume responsibility for manufacturing and its intent to assume the registrations of the therapeutic. Aratana believes the transfers of manufacturing and the registration in the U.S. to Elanco will be completed by December 31, 2017.

Research and development expenses totaled $3.7 million in the second quarter ended June 30, 2017 in comparison to $5.3 million for the quarter ended June 30, 2016. The decrease was primarily due to lower milestone payments as compared to 2016.

Selling, general and administrative expenses totaled $6.9 million for the second quarter ended June 30, 2017 compared to $6.1 million for the corresponding period in 2016. The increase is primarily related to the expanded commercial organization. Aratana expects selling, general and administrative expenses to remain relatively consistent through the remainder of 2017 with the corporate infrastructure substantially in place to support the commercialization of NOCITA and GALLIPRANT, as well as the anticipated commercialization of ENTYCE.

As of June 30, 2017, Aratana had approximately $80.7 million in cash, cash equivalents, restricted cash and short-term investments, which includes approximately $26.0 million in net proceeds from the sale of shares of the Company's common stock in the second quarter of 2017.

For the full year 2017, the Company continues to estimate operating expenses of approximately $45 million, resulting in a year-end cash balance of approximately $65 million.

The Company believes that its existing cash, cash equivalents, short-term investments and restricted cash of $80.7 million as of June 30, 2017 will allow Aratana to fund the current operating plan and debt obligations through at least 2018. The Company's current operating plan contemplates the launch of ENTYCE by the fall of 2017, as well as continued growth of our commercially available therapeutics.

Webcast & Conference Call Details

The Company will host a live conference call on Friday, August 4, 2017 at 8:30 a.m. ET to discuss financial results from the second quarter ended June 30, 2017.

Interested participants and investors may access the audio webcast or use the conference call dial-in:

1 (866) 364-3820 (U.S.) 1 (855) 669-9657 (Canada) 1 (412) 902-4210 (International)

A replay of the second quarter results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10110825:

1 (877) 344-7529 (U.S.) 1 (855) 669-9658 (Canada) 1 (412) 317-0088 (International)

IMPORTANT SAFETY INFORMATION

GALLIPRANT (grapiprant tablets) is not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see full product label for fullprescribing information.

ENTYCE (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the fullPrescribing Informationfor more detail.

NOCITA (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCI, lidocaine or other amide local anesthetics. Please see the fullPrescribing Informationfor more detail.

About Aratana Therapeutics

Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The Company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit http://www.aratana.com.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements with respect to anticipated financial performance, our ability to bring innovative therapeutics to the market; steps necessary for and timing of regulatory submissions and approvals of therapeutic candidates; study, development and commercialization of therapeutics or therapeutic candidates; timing of anticipated study results; increased market recognition of and demand for our therapeutics; Elanco's intent to assume responsibility for manufacturing and regulatory approval for GALLIPRANT under the Collaboration Agreement; our belief that if our prior approval submission is approved, the Company would be able to make ENTYCE commercially available by the fall of 2017, depending on the timing of CVM's approval, if any, of the PAS; expectations regarding trends in cost of product sales; anticipated 2017 operating expenses and year-end cash balance; and statements regarding the Company's efforts, plans and opportunities, including, without limitation, advancing our therapeutic candidates and offering innovative therapeutics that help manage pet's medical needs safely and effectively and that result in longer and improved quality of life for pets.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risk that the securities offering will not close in the timeframe we expect, or at all; the amount of net proceeds we receive from such offering and how we use them may differ from our current expectations; our history of operating losses and our expectation that we will continue to incur losses for the foreseeable future; failure to obtain sufficient capital to fund our operations; risks relating to the impairment of intangible assets, including BLONTRESS, TACTRESS, AT-007 and AT-011; risks pertaining to stockholder class action lawsuits; unstable market and economic conditions; restrictions on our financial flexibility due to the terms of our credit facility; our substantial dependence upon the commercial success of our therapeutics; development of our biologic therapeutic candidates is dependent upon relatively novel technologies and uncertain regulatory pathways, and biologics may not be commercially viable; denial or delay of regulatory approval for our existing or future therapeutic candidates; failure of our therapeutic candidates that receive regulatory approval to achieve market acceptance or achieve commercial success; product liability lawsuits that could cause us to incur substantial liabilities and limit commercialization of current and future therapeutics; failure to realize anticipated benefits of our acquisitions and difficulties associated with integrating the acquired businesses; development of pet therapeutics is a lengthy and expensive process with an uncertain outcome; competition in the pet therapeutics market, including from generic alternatives to our therapeutic candidates, and failure to compete effectively; failure to identify, license or acquire, develop and commercialize additional therapeutic candidates; failure to attract and retain senior management and key scientific personnel; our reliance on third-party manufacturers, suppliers and partners; regulatory restrictions on the marketing of our approved therapeutics and therapeutic candidates; our small commercial sales organization, and any failure to create a sales force or collaborate with third-parties to commercialize our approved therapeutics and therapeutic candidates; difficulties in managing the growth of our company; significant costs of being a public company; risks related to the restatement of our financial statements for the year ended December 31, 2013, and the identification of a material weakness in our internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our veterinarian customers; limitations on our ability to use our net operating loss carryforwards; impacts of generic products; safety or efficacy concerns with respect to our therapeutic candidates; effects of system failures or security breaches; delay or termination of the development of grapiprant therapeutic candidates and commercialization of grapiprant products that may arise from termination of or failure to perform under the collaboration agreement and/or the co-promotion agreement with Elanco; failure to obtain ownership of issued patents covering our therapeutic candidates or failure to prosecute or enforce licensed patents; failure to comply with our obligations under our license agreements; effects of patent or other intellectual property lawsuits; failure to protect our intellectual property; changing patent laws and regulations; non-compliance with any legal or regulatory requirements; litigation resulting from the misuse of our confidential information; the uncertainty of the regulatory approval process and the costs associated with government regulation of our therapeutic candidates; failure to obtain regulatory approvals in foreign jurisdictions; effects of legislative or regulatory reform with respect to pet therapeutics; the volatility of the price of our common stock; our status as an emerging growth company, which could make our common stock less attractive to investors; dilution of our common stock as a result of future financings; the influence of certain significant stockholders over our business; and provisions in our charter documents and under Delaware law could delay or prevent a change in control. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 14, 2017, along with our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts For investor inquires: Craig Toomanrel="nofollow">ctooman@aratana.com(913) 353-1026

For media inquiries: Rachel Reiffrel="nofollow">rreiff@aratana.com(913) 353-1050

ARATANA THERAPEUTICS, INC.

Consolidated Statements of Operations (Unaudited)

(Amounts in thousands, except share and per share data)

Three Months Ended

Six Months Ended

June 30,

June 30,

2017

2016

2017

2016

Revenues

Licensing and collaboration revenue

$

804

$

38,000

$

1,707

$

38,151

Product sales

4,354

47

7,246

68

Total revenues

5,158

38,047

8,953

38,219

Costs and expenses

Cost of product sales

3,691

1,741

6,785

1,760

Royalty expense

353

20

676

38

Research and development

3,700

5,303

8,354

16,052

Selling, general and administrative

6,918

6,148

14,413

12,699

Amortization of intangible assets

86

95

150

190

Impairment of intangible assets

2,780

2,780

Total costs and expenses

14,748

16,087

30,378

33,519

Originally posted here:
Aratana Therapeutics Reports Second Quarter 2017 Financial Results - Markets Insider

"We are pleased with the continued customer adoption of Galliprant and Nocita," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "In addition, we continue to advance our next wave of therapeutic candidates as evidenced by several recent regulatory submissions and a positive pivotal efficacy study in cats."

Recent Updates

Financial Results

The second quarter net loss was $10.4 million or $0.26 diluted loss per share compared to net income of $21.2 million or $0.61 diluted net income per share for the corresponding quarter ended June 30, 2016. Aratana recorded $5.2 million in net revenues for the quarter ended June 30, 2017, which primarily includes approximately $3.7 million related to GALLIPRANT product sales as finished goods under its supply arrangement with Elanco, $804 thousand in GALLIPRANT licensing and collaboration revenue, and $637 thousand in NOCITA net product sales. The second quarter of 2016 included $38.1 million in net revenues of which, $38.0 million was the result of the GALLIPRANT Collaboration Agreement.

The cost of product sales totaled $3.7 million in the second quarter of 2017 in comparison to $1.7 million for the corresponding period in 2016. The increase in the second quarter of 2017 was primarily due to GALLIPRANT supply sold to Elanco for commercial distribution, as well as cost of product sales of NOCITA. In July, pursuant to our Collaboration Agreement, Elanco provided notice of its intent to assume responsibility for manufacturing and its intent to assume the registrations of the therapeutic. Aratana believes the transfers of manufacturing and the registration in the U.S. to Elanco will be completed by December 31, 2017.

Research and development expenses totaled $3.7 million in the second quarter ended June 30, 2017 in comparison to $5.3 million for the quarter ended June 30, 2016. The decrease was primarily due to lower milestone payments as compared to 2016.

Selling, general and administrative expenses totaled $6.9 million for the second quarter ended June 30, 2017 compared to $6.1 million for the corresponding period in 2016. The increase is primarily related to the expanded commercial organization. Aratana expects selling, general and administrative expenses to remain relatively consistent through the remainder of 2017 with the corporate infrastructure substantially in place to support the commercialization of NOCITA and GALLIPRANT, as well as the anticipated commercialization of ENTYCE.

As of June 30, 2017, Aratana had approximately $80.7 million in cash, cash equivalents, restricted cash and short-term investments, which includes approximately $26.0 million in net proceeds from the sale of shares of the Company's common stock in the second quarter of 2017.

For the full year 2017, the Company continues to estimate operating expenses of approximately $45 million, resulting in a year-end cash balance of approximately $65 million.

The Company believes that its existing cash, cash equivalents, short-term investments and restricted cash of $80.7 million as of June 30, 2017 will allow Aratana to fund the current operating plan and debt obligations through at least 2018. The Company's current operating plan contemplates the launch of ENTYCE by the fall of 2017, as well as continued growth of our commercially available therapeutics.

Webcast & Conference Call Details

The Company will host a live conference call on Friday, August 4, 2017 at 8:30 a.m. ET to discuss financial results from the second quarter ended June 30, 2017.

Interested participants and investors may access the audio webcast or use the conference call dial-in:

1 (866) 364-3820 (U.S.) 1 (855) 669-9657 (Canada) 1 (412) 902-4210 (International)

A replay of the second quarter results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10110825:

1 (877) 344-7529 (U.S.) 1 (855) 669-9658 (Canada) 1 (412) 317-0088 (International)

IMPORTANT SAFETY INFORMATION

GALLIPRANT (grapiprant tablets) is not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see full product label for fullprescribing information.

ENTYCE (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the fullPrescribing Informationfor more detail.

NOCITA (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCI, lidocaine or other amide local anesthetics. Please see the fullPrescribing Informationfor more detail.

About Aratana Therapeutics

Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The Company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit http://www.aratana.com.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements with respect to anticipated financial performance, our ability to bring innovative therapeutics to the market; steps necessary for and timing of regulatory submissions and approvals of therapeutic candidates; study, development and commercialization of therapeutics or therapeutic candidates; timing of anticipated study results; increased market recognition of and demand for our therapeutics; Elanco's intent to assume responsibility for manufacturing and regulatory approval for GALLIPRANT under the Collaboration Agreement; our belief that if our prior approval submission is approved, the Company would be able to make ENTYCE commercially available by the fall of 2017, depending on the timing of CVM's approval, if any, of the PAS; expectations regarding trends in cost of product sales; anticipated 2017 operating expenses and year-end cash balance; and statements regarding the Company's efforts, plans and opportunities, including, without limitation, advancing our therapeutic candidates and offering innovative therapeutics that help manage pet's medical needs safely and effectively and that result in longer and improved quality of life for pets.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risk that the securities offering will not close in the timeframe we expect, or at all; the amount of net proceeds we receive from such offering and how we use them may differ from our current expectations; our history of operating losses and our expectation that we will continue to incur losses for the foreseeable future; failure to obtain sufficient capital to fund our operations; risks relating to the impairment of intangible assets, including BLONTRESS, TACTRESS, AT-007 and AT-011; risks pertaining to stockholder class action lawsuits; unstable market and economic conditions; restrictions on our financial flexibility due to the terms of our credit facility; our substantial dependence upon the commercial success of our therapeutics; development of our biologic therapeutic candidates is dependent upon relatively novel technologies and uncertain regulatory pathways, and biologics may not be commercially viable; denial or delay of regulatory approval for our existing or future therapeutic candidates; failure of our therapeutic candidates that receive regulatory approval to achieve market acceptance or achieve commercial success; product liability lawsuits that could cause us to incur substantial liabilities and limit commercialization of current and future therapeutics; failure to realize anticipated benefits of our acquisitions and difficulties associated with integrating the acquired businesses; development of pet therapeutics is a lengthy and expensive process with an uncertain outcome; competition in the pet therapeutics market, including from generic alternatives to our therapeutic candidates, and failure to compete effectively; failure to identify, license or acquire, develop and commercialize additional therapeutic candidates; failure to attract and retain senior management and key scientific personnel; our reliance on third-party manufacturers, suppliers and partners; regulatory restrictions on the marketing of our approved therapeutics and therapeutic candidates; our small commercial sales organization, and any failure to create a sales force or collaborate with third-parties to commercialize our approved therapeutics and therapeutic candidates; difficulties in managing the growth of our company; significant costs of being a public company; risks related to the restatement of our financial statements for the year ended December 31, 2013, and the identification of a material weakness in our internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our veterinarian customers; limitations on our ability to use our net operating loss carryforwards; impacts of generic products; safety or efficacy concerns with respect to our therapeutic candidates; effects of system failures or security breaches; delay or termination of the development of grapiprant therapeutic candidates and commercialization of grapiprant products that may arise from termination of or failure to perform under the collaboration agreement and/or the co-promotion agreement with Elanco; failure to obtain ownership of issued patents covering our therapeutic candidates or failure to prosecute or enforce licensed patents; failure to comply with our obligations under our license agreements; effects of patent or other intellectual property lawsuits; failure to protect our intellectual property; changing patent laws and regulations; non-compliance with any legal or regulatory requirements; litigation resulting from the misuse of our confidential information; the uncertainty of the regulatory approval process and the costs associated with government regulation of our therapeutic candidates; failure to obtain regulatory approvals in foreign jurisdictions; effects of legislative or regulatory reform with respect to pet therapeutics; the volatility of the price of our common stock; our status as an emerging growth company, which could make our common stock less attractive to investors; dilution of our common stock as a result of future financings; the influence of certain significant stockholders over our business; and provisions in our charter documents and under Delaware law could delay or prevent a change in control. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 14, 2017, along with our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts For investor inquires: Craig Toomanctooman@aratana.com (913) 353-1026

For media inquiries: Rachel Reiffrreiff@aratana.com (913) 353-1050

ARATANA THERAPEUTICS, INC.

Consolidated Statements of Operations (Unaudited)

(Amounts in thousands, except share and per share data)

Three Months Ended

Six Months Ended

June 30,

June 30,

2017

2016

2017

2016

Revenues

Licensing and collaboration revenue

$

804

$

38,000

$

1,707

$

38,151

Product sales

4,354

47

7,246

68

Total revenues

5,158

38,047

8,953

38,219

Costs and expenses

Cost of product sales

3,691

1,741

6,785

1,760

Royalty expense

353

20

676

38

Research and development

3,700

5,303

8,354

16,052

Selling, general and administrative

6,918

6,148

14,413

12,699

Amortization of intangible assets

86

95

150

190

Impairment of intangible assets

2,780

2,780

Total costs and expenses

14,748

16,087

30,378

33,519

Income (loss) from operations

(9,590)

21,960

(21,425)

Read the original post:
Aratana Therapeutics Reports Second Quarter 2017 Financial Results - PR Newswire (press release)

Aratana Therapeutics (PETX) is a $290 million market cap veterinary biotechnology company with sole focus on how to solve unmet and under-served medical needs in pets with serious diseases. The company is working to pass animal therapeutics from the bottom to the top, through stages of formulation, preclinical and clinical studies, regulatory approval, manufacturing, and commercialization. The company is regarded as a leader in developing drugs for use by pets. The company has two products approved for animal pain, with several candidates with market launch dates anticipated soon. Galliprant is approved for use in dogs for control of pain and inflammation associated with osteoarthritis. Nocita is approved for post-cranial cruciate ligament surgery pain. Two cancer drugs, tactress and blontress for use in T-cell and B-cell lymphoma are also conditionally and fully available to veterinarians via USDA agreement, respectively. The company is in the final stages of regulatory process Entyce, a drug for appetite stimulation in dogs, with potential launch in fall 2017. PETX anticipates USDA license for candidate AT-014 in canine osteosarcoma in 2H 2017. Candidate AT-016 is being developed with collaborator VetStem BioPharma for osteoarthritis pain in dogs, with results of this pivotal safety study expected in 2017. This study is particularly interesting to Strong Bio, and stands out in the veterinary market targeting companies, because AT-016 is an adipose-derived allogeneic stem cell therapeutic. The combined 2015 estimated markets for pet pharmaceuticals came in at about $7.5 billion dollars.

Galliprant (grapiprant tablets) is an orally administered first-in-class piprant (a non-COX-inhibiting prostaglandin EP4 receptor antagonist) indicated for osteoarthritis pain and inflammation in dogs. The drug is in co-promotion with Elanco Animal Health, a division of Eli Lilly (LLY). Elanco has exclusive rights to develop, manufacture and market Galliprant globally. Galliprant demonstrated statistically significant in pain measures in a four week placebo-controlled study of 285 dogs. A nine month safety study dosed animals with 15-fold increase over normal dosing regimen, and showed no clinically significant changes in liver, kidney, blood, or reaction parameters. The most common adverse reactions were vomiting, diarrhea, decreased appetite and lethargy. PETX reports that the drug can be used by puppies as young as 9 months (or weighing 8 pounds or more), with half or full tablet once-daily dosing. The drug was commercially available in January 2017, with FDA CVM approval coming in 2016. EMA submissions took place in 2016 with estimated approvals in 2017. It is estimated that one in five dogs suffers from osteoarthritis, with an increasingly competitive (PetVivo (OTCPK:PETV) and Zoetis (ZTS)) market estimated at nearly $3 billion.

Nocita (bupivacaine liposome injectable suspension, AT-002) gained FDA CVM approval for local post-operative analgesia for cranial cruciate ligament surgery in dogs in 2016. One administration has a relatively long-lasting 72 hour effective window, releasing bupivacaine over time from liposome suspension. It became commercially available in October 2016. "We believe Nocita will help transform the way veterinarians control post-operative pain for dogs undergoing cranial cruciate ligament surgery," stated Steven St. Peter M.D. in the company announcement, President and Chief Executive Officer of Aratana Therapeutics. Adverse reactions in dogs included discharge from incision, incisional inflammation, and vomiting. Logical label expansion for the drug would be other related surgeries, international expansion, and use in other animals. AT-003 is being developed by PETX for post-operative pain in cats, currently in pivotal studies.

The company has two cancer medications for animals, Tactress and Blontress. PETX was granted conditional licensure of Tactress1 (AT-005), a monoclonal antibody for use in dogs with T-cell lymphoma, by USDA Center for Veterinary Biologics in 2014. Final labeling awaits USDA approval, with the therapeutic currently available to veterinary oncologists under conditional license from USDA. Blontress (AT-004) novel B-cell lymphoma monoclonal antibody for use in dogs was given full license from USDA. Blontress is partnered with a third party for U.S. and Canada commercialization. PETX retains development and commercialization rights for other geographies. B-cell lymphoma is a common cancer in dogs, and progresses quickly if untreated. Because chemotherapy, the treatment of choice in lymphoma, has a lot of undesired treatment effects, better therapies are needed. A third anti-cancer immunotherapy, AT-014, is being developed with a product license with USDA for osteosarcoma in dogs. The company is a pioneer in the canine cancer space. It was estimated that in 2015 pet owners shelled out over $15 billion dollars for cancer treatment in animals, with $500 million being estimated for dogs alone.

ENTYCE (capromorelin oral solution; ghrelin receptor agonist) development is in final approval stages for appetite stimulation in dogs, having been approved by FDA in June 2016. PETX presented data from a study of 244 dogs at American College of Veterinary Internal Medicine in June 2016, reporting that 68.6% of pets taking Entyce had an increase in appetite (as reported by owners; 44.6% for placebo). 56.2% of the Entyce treated dogs displayed increased appetite-related behaviors compared to 26.8% of placebo. 76% of the dogs gained weight on Entyce, in contrast to 45% of placebo dogs, over the four day study period. In an April 2017 update, PETX announced it recently met with FDA Center for Veterinary Medicine (CVM) regarding manufacture of ENTYCE. The company anticipates that upon approval from FDA CVM it can begin its sole commercialization launch in the fall of 2017. Entyce label expansion study for weight management in cats with chronic kidney disease initiated in Q1 2017. Ghrelin receptor agonists have demonstrated anti-inflammation, vasodilation, increased cardiac output and vascular resistance, and increased IGF-1 levels. Thus label expansion in the future could include such indications as anorexia, negative energy balance, chronic heart failure, inflammation, chemotherapy, arthritis, inflammatory bowel disease, and gastroparesis.

PETX reported a 1Q 2017 loss of $12.6 million, compared to prior 1Q 2016 loss of $18.1 million. $3.8 million in net revenues was primarily received from Galliprant sales ($2.5 million) and $300 thousand in Nocita sales. The company reported $68 million in cash on hand at end Q1 2017, and raised an additional $24.4 million in a May 2017 equity offering of 5 million shares at $5.25 per share. Aratana expects Galliprant sales to continue to grow into one of the top pet products in the U.S., and as it reaches milestone payments from Elanco, contribute significantly to the company bottom line. PETX expects to launch Entyce during the fall of 2017, potentially helping enable the company to reach early 2019 with current cash on hand.

Because studies in animals are much less expensive to conduct than large scale international clinical trials, the company's threshold for drug approval is easier to attain in terms of financing, provided its candidates demonstrate solid efficacy. It is also less rigorous from a regulatory perspective to gain approval of animal products. Challenges for manufacturing appear to be significant, but manageable. The company has a number of candidates in development, forming a promising pipeline, and its sales are increasing, and it will be interesting to see how this sales data compares with launches for drugs to treat humans, and how label expansion efforts go from species to species. Most interesting of all are its efforts in development of allogeneic stem cell treatments for canine osteoarthritis. Perhaps stem cell advances in pet therapies will finally usher in new therapies for humans, which seems to have hit resistance for a number of social and regulatory reasons. Moreover, there is a success model for animal treatment companies like ZTS, which should provide the market a basis for PETX share ascension. Still, with a market cap of under or near $300 million, and large addressable markets, it looks like a good place for an initial position to Strong Bio anywhere around $7 per share.

Risks specific to PETX would be market uncertainty as well as competition. For instance, even though appetite stimulation in dogs has a market, cannabinoids would be regarded by Strong Bio as having shown better efficacy, and may be sold at significantly less expensive prices. Still, these mechanisms are separate, and veterinarians should appreciate having more options. Cancer treatment markets for pets are expected by several experts in the field to burgeon in the coming years. However, information on the actual study data for blontress and tactress is difficult to find, making it hard recommend PETX stock without using words like "potential" until more information on these studies is made available. If the reader knows where information can be found feel free to add it in the comments section. Stem cell therapies, although promising, are unproven as well, and will require time to elucidate functionality and efficacy.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Follow this link:
Is Aratana Your Porfolio's Best Friend? - Seeking Alpha

Hormone replacement therapies, or medications containing female hormones that substitute those no longer produced by the body, often are prescribed to reduce the effects of menopausal symptoms in women. Research has indicated that women who take hormone replacement therapies have a higher incidence of breast cancer.

Hormone replacement therapies, or medications containing female hormones that substitute those no longer produced by the body, often are prescribed to reduce the effects of menopausal symptoms in women. Research has indicated that women who take hormone replacement therapies have a higher incidence of breast cancer.

Now, researchers at theUniversity of Missouri have linked natural and synthetic progestins to the bodys production of specialized cancer cells that act like stem cells in humans. Findings could help scientists target these rare cells that proliferate in breast cancers and metastasize elsewhere, and may help clinicians identify immunotherapies to combat the spread of the disease.

In previous studies, we have shown that both natural and synthetic progestins accelerate the development of breast cancer and increase their metastasis to lymph nodes, said Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. Our laboratory is committed to identifying the cell mechanisms that bring about increased breast cancer risks. Recently, our research focused on special cells which are called cancer stem cell-like cells that induce aggressive tumor growth, metastasis and cancer recurrence.

In a series of tests, the team used hormone-responsive human breast cancer cells to examine the effects of progestin on the cell markers typically found in breast cancers. Both natural and synthetic progestins significantly increased protein expression of CD44, a molecule involved in cell proliferation, cell communication and migration. Additionally, the presence of progestins caused these components to behave like cancer stem cell-like cells.

These rare cells are a small population of cells that acting like normal stem cells are self-renewing, create identical copies of themselves and proliferate exponentially. Further testing showed that the rare subset of cancer cells actually was enriched by progestin.

The findings show that exposure to natural and synthetic progestins leads to the development of these cancer stem-cell like cells, Hyder said. These cells greatly increase the likelihood of resistance to therapies and the risk for metastasis. Our findings also suggest that clinicians may be able to combat the progestin-dependent tumor growth through immunotherapy.

Researchers involved with the study included Sandy Goyette, a graduate student in Hyders lab; Yayun Liang, a research associate professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center at MU; Benford Mafuvadze, formerly a post-doctoral fellow in Hyders lab; Matthew T. Cook, a recent doctoral graduate and research scientist at Dalton Cardiovascular Research Center; and Moiz Munir, a Division of Biological Sciences and Capstone Scholar in Hyders lab.

The study, Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro, available at https://www.dovepress.com/natural-and-synthetic-progestins-enrich-cancer-stem-cell-like-cells-in-peer-reviewed-fulltext-article-BCTT , recently was published in Breast Cancer Targets and Therapy with funding provided through the College of Veterinary Medicine Committee on Research and the generosity of donors to the Ellis Fischel Cancer Center at MU. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Read this article:
MU researchers find link between hormone-replacement therapy, breast cancer growth - Hannibal.net

Imunnotherapy for cancer is experiencing a resurgence and is being studied to provide an affordable option for the treatment of cancer in dogs.

Lexington, KY (PRWEB) July 11, 2017

MediVet Biologics, a global leader in veterinary biologic solutions for pets announced today in partnership with the Veterinary Cancer Group (Los Angeles, CA) a trial for dogs stricken with cancer. The trial involves a breakthrough strategy of combining a personalized immunotherapy vaccine with specialty cancer standards of care.

K9ACV is a service provided by MediVet Biologics which allows for an affordable personalized immunotherapy vaccine for canine cancer. The immunotherapy cancer vaccine was developed by MediVet Biologics in partnership with researchers from the University of Kentucky Markey Cancer Center.

Immunotherapy is a cutting-edge strategy designed to assist the patient's own immune system to work harder and more efficiently to attack cancer from within.

K9ACV is being studied by the veterinarian oncology team at Veterinary Cancer Group to be used in conjunction with current treatment strategies such as chemotherapy and radiation. The goal, is to study a multi modal approach to canine cancer to see if it can offer better outcomes when patients are in various stages of disease.

Greater than 50% of dogs over the age of ten will develop cancer and early detection is often difficult. The trial is now open and available to owners of canine patients with any form of cancer in the Orange County, San Fernando Valley & Los Angeles California areas.

In late 2016, an initial paper was published on the vaccine service and the company just finished an additional trial utilizing the vaccine for cancer patients at Kansas State University College of Veterinary Medicine.

Thomas Masterson, VP of Business Development, MediVet Biologics, "We have already had tremendous success utilizing K9ACV on patients who were not candidates for specialty cancer care. Our hope is that by combining our immunotherapy treatment with other established methodologies of canine oncology care we can make this service available to more patients in need and offer increased survival for the patient. We are fortunate to have partnered with a progressive group of oncologists such as the team at VCG."

About MediVet Biologics

MediVet Biologics is a animal health company focused on providing innovative strategies to fight diseases and redefine pet healthcare. Since 2010 the company has provided services to a network of thousands of progressive veterinarians such as Actistem Stem Cell Therapy and other biologic treatments designed to rebuild and repair processes naturally without dependency on drugs. Each product and service is designed to offer alternatives to improve the lives of pets and their owners. http://www.medivetbiologics.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/07/prweb14494704.htm

Read this article:
MediVet Biologics Launches Innovative Immunotherapy Trial for Canine Cancer - Benzinga

Dr. John Schultz gives an injection of bone marrow derived stem cells into the knee of patient Steve Brink from Washington state at the Regenexx offices in Broomfield June 12. (Paul Aiken / Staff Photographer)

_Broomfield's Regenexx, a stem cell treatment network, has completed its merger with Des Moines, Iowa-based Harbor View Medical.

The company corporate headquarters will move to Des Moines as a result, with the company's medical headquarters remaining in Broomfield, according to spokeswoman Caroline Patterson.

Patterson there would be no layoffs in Broomfield as a result of the merger.

Regenexx co-founder, Dr. Christopher Centeno, a pioneer in using stem cells to treat orthopedic injuries, will maintain his role as chief medical officer and Jason Hellickson will become CEO.

Regenexx treatments include injection of a patient's own stem cells and platelet-rich plasma (PRP) to encourage healing of tendons, joints and muscles.

"Most of what we currently call orthopedic surgery will, in the next 10-20 years, be in the dust bin of history," Centano told the Daily Camera last month. "Thirty years from now, cutting people open and drilling holes will be considered barbaric."

Despite advances in research, critics say the safety and effectiveness of these regenerative treatments is largely unregulated and remains poorly understood.

A study by Mayo Clinic, whose results were published last year, noted that patients in a blind study, who had arthritis in both knees, saw benefits from the treatment, but that it wasn't clear why. Just one knee had actually been injected with the stem cells.

The stem cell treatments,have generated controversy among some medical professionals because they cost thousands of dollars and have not been widely studied. Last year the U.S. Food and Drug Administration (FDA) held a series of scientific meetings examining how best to regulate and ensure the safety and efficacy of this approach.

The Mayo Clinic study, overseen by the FDA, concluded that the procedure it sstudied was safe to undergo, but it was not ready to recommend it for "routine arthritis care."

Still the use of stem cell treatments in everything from veterinary clinics to dermatology orthopedic practices is growing. Founded in 2005, Regenexx lists 48 clinics worldwide, including a new facility it opened in Mumbai this month.

Jerd Smith: 303-473-1332, smithj@dailycamera.com or twitter.com/jerd_smith

Read more:
Broomfield's Regenexx in merger with Iowa company - The Daily Camera